Assignee
NAVIDEA BIOPHARMACEUTICALS INC
US·12 granted patents·17 pending applications·14 citations·filing 2013–2025
Top patents by PatentIndex Score
29 records- 0191US11833170B2Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blockingNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Granted Dec 5, 2023·2 cites·16 claims
- 0290US11007272B1Compounds and methods for diagnosis and treatment of viral infectionsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2017·Granted May 18, 2021·6 cites·12 claims
- 0382US11590236B2Compositions and methods for altering macrophage phenotypeNAVIDEA BIOPHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·1 cites·9 claims
- 0481US12404349B2Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymersNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Granted Sep 2, 2025·0 cites·19 claims
- 0581US11369680B2Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using sameNAVIDEA BIOPHARMACEUTICALS INC·Filed 2017·Granted Jun 28, 2022·2 cites·11 claims
- 0679US12583945B2Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereofNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Granted Mar 24, 2026·0 cites·8 claims
- 0779US9439985B2Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextranNAVIDEA BIOPHARMACEUTICALS INC·Filed 2013·Granted Sep 13, 2016·3 cites·22 claims
- 0879US2025382392A1Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymersNAVIDEA BIOPHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0977US12297222B2CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linkerNAVIDEA BIOPHARMACEUTICALS INC·Filed 2024·Granted May 13, 2025·0 cites·13 claims
- 1077US2025325681A1Compositions and methods for altering macrophage phenotypeNAVIDEA BIOPHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1175US12178829B2Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blockingNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Granted Dec 31, 2024·0 cites·20 claims
- 1275US12006339B2CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linkerNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·0 cites·31 claims
- 1374US2023218770A1Compositions and methods for altering macrophage phenotypeNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1473US11859023B2Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereofNAVIDEA BIOPHARMACEUTICALS INC·Filed 2021·Granted Jan 2, 2024·0 cites·19 claims
- 1570US12005122B2Compounds and methods for diagnosis and treatment of viral infectionsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2021·Granted Jun 11, 2024·0 cites·20 claims
- 1667US2023210998A1Methods for the conjugation of anthracyclines to carbohydrate polymeric carriersNAVIDEA BIOPHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1763US2016206763A1Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using sameNAVIDEA BIOPHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1862US2023302041A1Competitive Self-Blocking with Unlabeled Manocept Imaging AgentsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1961US2024024491A1Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cellsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2060US2023070258A1Compositions and methods for the treatment of rheumatoid arthritisNAVIDEA BIOPHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2156US2016347679A1Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextranNAVIDEA BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2253US2020237937A1Compositions and methods for assessing macrophage mediated pathologyNAVIDEA BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2353US2021145989A1Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligandsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2452US2015023876A1Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disordersNAVIDEA BIOPHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2551US2021052639A1Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cellsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2648US2019022259A1Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventionsNAVIDEA BIOPHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2745US2014079634A1Labeled pe2i formulation and methodNAVIDEA BIOPHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2844US2019021608A1CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in HumansNAVIDEA BIOPHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2934US2018344881A1Formulations for 2-heteroaryl substituted benzofuransNAVIDEA BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NAVIDEA BIOPHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →